CDK12 and breast carcinoma: Notably, compared to the CDK12/13 inhibitor THZ531, the CDK12/13 degrader YJ9069 effectively inhibited cell proliferation in subsets of prostate and breast cancer cell lines preferentially over benign immortalized cells.